ATE408015T1 - Transfer system basierend auf einem fusionsprotein und seine anwendungen. - Google Patents

Transfer system basierend auf einem fusionsprotein und seine anwendungen.

Info

Publication number
ATE408015T1
ATE408015T1 AT96911739T AT96911739T ATE408015T1 AT E408015 T1 ATE408015 T1 AT E408015T1 AT 96911739 T AT96911739 T AT 96911739T AT 96911739 T AT96911739 T AT 96911739T AT E408015 T1 ATE408015 T1 AT E408015T1
Authority
AT
Austria
Prior art keywords
present
dna encoding
protein
lentiviral
composition
Prior art date
Application number
AT96911739T
Other languages
English (en)
Inventor
John Kappes
Xiaoyun Wu
Original Assignee
Univ Alabama Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alabama Res Found filed Critical Univ Alabama Res Found
Application granted granted Critical
Publication of ATE408015T1 publication Critical patent/ATE408015T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96911739T 1995-04-14 1996-04-12 Transfer system basierend auf einem fusionsprotein und seine anwendungen. ATE408015T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42198295A 1995-04-14 1995-04-14

Publications (1)

Publication Number Publication Date
ATE408015T1 true ATE408015T1 (de) 2008-09-15

Family

ID=23672889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96911739T ATE408015T1 (de) 1995-04-14 1996-04-12 Transfer system basierend auf einem fusionsprotein und seine anwendungen.

Country Status (6)

Country Link
US (5) US6001985A (de)
EP (1) EP0873415B1 (de)
AT (1) ATE408015T1 (de)
CA (1) CA2230925C (de)
DE (1) DE69637677D1 (de)
WO (1) WO1996032494A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US20020173643A1 (en) * 1995-04-14 2002-11-21 Kappes John C. Fusion protein delivery system and uses thereof
US6087486A (en) * 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
EP1053358A4 (de) * 1998-02-10 2002-08-14 Uab Research Foundation Verwendung von hiv-1 integrase beim screening von potentiellen hiv-1 arzneistoffen
EP1076715B1 (de) 1998-05-13 2007-07-18 Genetix Pharmaceuticals Inc. Lentivirale Verpackungszellen
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US6984486B1 (en) 1999-02-19 2006-01-10 J. David Gladstone Institutes Synthetic peptide of regulatory virus protein R (VPR) of human immunodeficiency virus type 1 (HIV-1) and the utilization thereof
AU5286500A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Methods to inhibit infectious agent transmission during xenotransplantation
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
CA2439620A1 (en) * 2001-03-02 2002-09-12 Merck & Co., Inc. Viral reporter particles
US8216585B2 (en) 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US7237559B2 (en) * 2001-08-14 2007-07-03 R.J. Reynolds Tobacco Company Wrapping materials for smoking articles
KR20040089096A (ko) * 2001-12-21 2004-10-20 트란지미, 인크. 렌티바이러스 벡터를 이용한 유전자 변형된 동물을제조하기 위한 방법 및 조성물
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7402436B2 (en) * 2004-05-03 2008-07-22 City Of Hope Lentiviral vectors for site-specific gene insertion
JP5558711B2 (ja) * 2005-05-31 2014-07-23 ダウ グローバル テクノロジーズ エルエルシー 塗料およびガラスの性能に対してプライマー非要求性であるポリウレタン封止剤組成物
WO2009131706A1 (en) * 2008-04-26 2009-10-29 Yung-Nien Chang Site-specific-integration lentiviral vectors
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE275259C (de) *
GB8818020D0 (en) * 1988-07-28 1988-09-01 Ici Plc Method for amplification of nucleotide sequences
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5175099A (en) * 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
EP0474797B1 (de) * 1989-06-02 1995-09-06 Dana Farber Cancer Institute Protein mit transaktivierender eigenschaft, dieses protein exprimierende vektoren, zellinien und seine verwendungen
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
EP0491930B1 (de) * 1990-07-12 1997-01-15 The President And Fellows Of Harvard College Primaten-lentivirus impfstoffe
US5989886A (en) 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
JPH08500965A (ja) * 1992-05-22 1996-02-06 デイナ ファーバー キャンサー インスチチュート ハイブリッドウイルス発現ベクター，その使用および新規アッセイ
WO1993025235A1 (en) * 1992-06-09 1993-12-23 President And Fellows Of Harvard College Aids therapeutics based on hiv-2 vpx peptides
AU5848794A (en) * 1993-02-05 1994-08-29 Regents Of The University Of California, The Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
WO1995016705A1 (en) * 1993-12-15 1995-06-22 The Trustees Of The University Of Pennsylvania Vpr receptor protein
CA2186398A1 (en) * 1994-03-25 1995-10-05 Ahmed A. Azad Vpr and vpx proteins of hiv
US5861161A (en) * 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5639619A (en) * 1994-10-13 1997-06-17 Regents Of The University Of California Screening assay for anti-HIV drugs using the Vpr gene
US6200811B1 (en) * 1996-04-02 2001-03-13 The Regents Of The University Of California Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein

Also Published As

Publication number Publication date
DE69637677D1 (de) 2008-10-23
EP0873415A1 (de) 1998-10-28
US20020151710A1 (en) 2002-10-17
WO1996032494A1 (en) 1996-10-17
CA2230925C (en) 2010-10-12
US6001985A (en) 1999-12-14
US6362000B1 (en) 2002-03-26
AU743113B2 (en) 2002-01-17
EP0873415A4 (de) 1999-09-08
CA2230925A1 (en) 1996-10-17
US7534603B2 (en) 2009-05-19
US20040010135A1 (en) 2004-01-15
EP0873415B1 (de) 2008-09-10
AU5482896A (en) 1996-10-30
US20030166563A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
DE69637677D1 (de) Transfer system basierend auf einem fusionsprotein und seine anwendungen.
ATE475713T1 (de) Trans-lentivirales vektor system
Sellers et al. Changing Fos oncoprotein to a Jun-independent DNA-binding protein with GCN4 dimerization specificity by swapping" leucine zippers"
Smith et al. Conserved surface-exposed K/RXK/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense
RU2225870C2 (ru) Способ разрушения клетки-мишени или инфекционного агента-мишени (варианты), химерный рецептор (варианты), днк (варианты), вектор (варианты)
Kim et al. Characterization of the nuclear export signal of human T-cell lymphotropic virus type 1 Rex reveals that nuclear export is mediated by position-variable hydrophobic interactions
Grassmann et al. In vitro binding of human T-cell leukemia virus rex proteins to the rex-response element of viral transcripts
DE69421624D1 (de) Medikamente bindendes protein
ES2134770T3 (es) Proteinas producidas por los linfocitos humanos, secuencia de adn codante para estas proteinas y aplicaciones farmaceuticas y biologicas.
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
ATE198910T1 (de) Retrovirale vektoren
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
Li et al. Modulation of activity of Moloney murine leukemia virus preintegration complexes by host factors in vitro
DE69534733D1 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
HUP9900868A2 (hu) Heterológ gének kromoszomális expressziója bakteriális sejtekben
YU150891A (sh) Rekombinantna genetska informacija
KR19980064289A (ko) 약리학적으로 통제가능한 자가 증진 발현 시스템
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
HUP9802681A1 (hu) Onkogénnel vagy vírussal szabályozott expressziós rendszerek
Yamada et al. Proline 78 is crucial for human immunodeficiency virus type 1 Nef to down-regulate class I human leukocyte antigen
Heger et al. Multimer formation is not essential for nuclear export of human T-cell leukemia virus type 1 Rex trans-activator protein
Chevalier et al. Presence of a functional but dispensable nuclear export signal in the HTLV-2 Tax protein
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
Lee et al. Characterization of functional domains of equine infectious anemia virus Rev suggests a bipartite RNA-binding domain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties